Metagenomi Inc
MGX
查看详细走势图
1.540USD
+0.130+9.22%
收盘 02/06, 16:00（美东）报价延迟15分钟
57.82M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+9.22%
5天
0.00%
1月
-14.44%
6月
-19.79%
今年开始到现在
-4.94%
1年
-37.90%
查看详细走势图
TradingKey Metagenomi Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
Metagenomi Inc当前公司基本面数据相对健康，最新ESG披露属于行业中等水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名113/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价9.33。中期看，股价处于下降通道。近一个月，市场表现较差，但基本面评分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Metagenomi Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Metagenomi Inc亮点
亮点风险
Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
业绩高增长
公司营业收入稳步增长，连续3年增长204.04%
业绩增长期
公司处于发展阶段，最新年度总收入52.30M美元
利润高增长
公司净利润处于行业前列，最新年度总收入52.30M美元
估值高估
公司最新PE估值-0.64，处于3年历史高位
机构减仓
最新机构持股6.70M股，环比减少56.89%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值1.27M
分析师目标
根据
5
位分析师
买入
评级
9.333
目标均价
+543.68%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Metagenomi Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Metagenomi Inc简介
Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
公司代码MGX
公司Metagenomi Inc
CEOIrish (Jian)
网址https://metagenomi.co/
相关品种
